Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 16;230(2):421-425.
doi: 10.1093/infdis/jiae168.

Mitochondrial Haplogroups and Weight Gain After Initiating ART in Patients With HIV

Juan Berenguer  1   2   3 , Inmaculada Jarrín  3   4 , José M Bellón  1   2   3 , Cristina Díez  1   2   3 , María A Jiménez-Sousa  3   5 , Juan C López  1   2   3 , Adriana Pinto-Martínez  3   6   7 , Santiago Moreno  3   8   9 , María L Montes  3   10   11 , José A Iribarren  12   13 , Eva Orviz  3   14   15 , Joaquín Portilla  16 , Francesc Villarroya  17   18 , Pere Domingo  19 , Salvador Resino  3   5 ; CoRIS Cohort
Collaborators, Affiliations

Mitochondrial Haplogroups and Weight Gain After Initiating ART in Patients With HIV

Juan Berenguer et al. J Infect Dis. .

Abstract

We studied the association of mitochondrial DNA (mtDNA) haplogroups with weight and body mass index (BMI) gain at 96 weeks in 1019 treatment-naive persons with HIV (PWH) who initiated first-line antiretroviral therapy (ART) since 2014. The mean increase in weight and BMI over the study period was 2.90 kg and 0.98 kg/m2, respectively. We found a significant adjusted association between the major UK mtDNA haplogroup and lower weight and BMI increase at 96 weeks after ART initiation. Our findings reveal a potential role for mitochondrial genetics in the complex phenomenon of weight gain after initial ART in PWH.

Keywords: HIV; antiretroviral therapy; genetics; mitochondrial DNA; weight gain.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. J. B. reports honoraria for advice or public speaking from Gilead, Glaxo Smith Kline (GSK), Janssen, Merck Sharp & Dohme (MSD), ViiV Healthcare; and grants from Gilead, MSD, and ViiV Healthcare. I. J. reports honoraria for advice or public speaking from Gilead and ViiV Healthcare; grants from MSD; and support for attending meetings and/or travel from Gilead. J. C. L. reports honoraria for advice or public speaking from Gilead, MSD, and ViiV Healthcare; grants from ViiV Healthcare; and support for attending meetings and/or travel from ViiV Healthcare and MSD. P. D. reports honoraria for advice or public speaking from Gilead, MSD, Janssen, and ViiV Healthcare. A. P.-M. reports honoraria for public speaking and support for attending meetings and/or travel from Gilead, MSD, Jannsen, and ViiV Healthcare. S. M. reports honoraria for advice or public speaking from Gilead, GSK, Janssen, MSD, and ViiV Healthcare; and grants from Gilead, MSD, and ViiV Healthcare. M. L. M. reports honoraria for advice or public speaking from AbbVie, BMS, Gilead, Jannsen, and ViiV Healthcare; and support for attending meetings and/or travel from ViiV Healthcare and Janssen. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.